What is the role of bortezomib-dexamethasone induction therapy in the treatment of multiple myeloma (MM)?

Updated: Sep 30, 2019
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

A study by Moreau et al determined that achievement of very good partial response (VGPR) after induction therapy is an important prognostic factor in patients undergoing autologous stem cell transplantation. [108] VGPR was significantly improved with bortezomib-dexamethasone induction therapy.

A study by Harousseau et al also concluded that this combination significantly improved postinduction and posttransplantation complete response/near response rate at at least VGPR rates compared with VAD. [109] Cavo et al also concluded that this combination represents a new standard of care for patients with multiple myeloma who are eligible for transplant. [110]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!